Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study-Reference-Cited by-全球学者库

Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study

Published:2022-10-01 Issue:4 Volume:187 Page:594-596
ISSN:1365-2133
Container-title:British Journal of Dermatology
language:en
Short-container-title:

Author:

Kato Junji¹^ORCID,Namikawa Kenjiro²^ORCID,Uehara Jiro³,Nomura Motoo⁴,Nakamura Yasuhiro⁵^ORCID,Uhara Hisashi¹,Uchi Hiroshi⁶,Yoshikawa Shusuke⁷,Kiniwa Yukiko⁸^ORCID,Nakamura Yoshiyuki⁹^ORCID,Miyagawa Takuya¹⁰,Matsushita Shigeto¹¹^ORCID,Takenouchi Tatsuya¹²^ORCID,Hatta Naohito¹³^ORCID,Ohno Fumitaka¹⁴,Maeda Taku¹⁵,Fukushima Satoshi¹⁶,Yamazaki Naoya²

Affiliation:

1. Department of Dermatology Sapporo Medical University Sapporo Japan

2. Department of Dermatologic Oncology National Cancer Center Hospital Tokyo Japan

3. Department of Dermatologic Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

4. Department of Clinical Oncology Kyoto University Kyoto Japan

5. Department of Skin Oncology/Dermatology Saitama Medical University International Medical Center Saitama Japan

6. Department of Dermato-Oncology National Hospital Organization Kyushu Cancer Center Fukuoka Japan

7. Dermatology Division Shizuoka Cancer Center Shizuoka Japan

8. Department of Dermatology Shinshu University Nagano Japan

9. Department of Dermatology University of Tsukuba Tsukuba Japan

10. Department of Dermatology University of Tokyo Graduate School of Medicine Tokyo Japan

11. Department of Dermato-Oncology/Dermatology National Hospital Organization Kagoshima Medical Center Kagoshima Japan

12. Department of Dermatology Niigata Cancer Center Niigata Japan

13. Department of Dermatology Toyama Prefectural Central Hospital Toyama Japan

14. Department of Dermatology Kyushu University Fukuoka Japan

15. Department of Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan

16. Department of Dermatology and Plastic Surgery Kumamoto University Kumamoto Japan

Abstract

Funder

National Cancer Center Research and Development Fund

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.21276

Reference8 articles.

1. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma;Robert;J Clin Oncol,2018

2. The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma;Ladwa;Melanoma Res,2017

3. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma;Jansen;Ann Oncol,2019

4. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma;Pokorny;J Immunother Cancer,2021

5. Real-world survival in patients with metastatic melanoma after discontinuation of anti-PD-1 immunotherapy for objective response or adverse effects: a retrospective study;Valentin;J Oncol,2021